Ginkgo Bioworks Holdings, Inc. (DNA)

Ginkgo Bioworks Holdings, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Ginkgo Bioworks Holdings, Inc. (DNA) is a Biotechnology company based in US with a market capitalization of $515.4M. Revenue declined 25.1% year-over-year and free cash flow was negative at -$178.7M. This page tracks DNA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 834 employees · IPO Apr 19, 2021

Valuation

Valuation & price

$7.71as of May 17, 2026· -52.2% vs 52w high

P/E ratio

Latest-FY diluted EPS

1.01

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$16.09$10.79$5.48Jul 25Jan 26Jul 26
$5.4852-week range$16.14
Loading valuation history…

Fundamentals

Key fundamentals

$515.4M

Market cap

-25.1%

Revenue growth (YoY)

81.5%

Gross margin

-$178.7M

Free cash flow (USD)

-$5.5M

Net debt

Net cash position

6.9%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20192025

$54.2M$170.2M

Free cash flow by year

20192025

-$66.9M-$178.7M

Gross margin by year

20212025

58.7%81.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellJul 20, 2026Filing

    Insider Sell $6KCoen Steven P. · See remarks · $5.9K

  • 8-K eventJun 12, 2026Filing

    Annual Meeting Results

  • Insider sellMay 26, 2026Filing

    Insider Sell $3KCoen Steven P. · See remarks · $2.6K

  • 8-K eventMay 7, 2026Filing

    Earnings Release

  • Quarterly reportMay 7, 2026Filing

    10-Q Filed

  • Insider sellApr 20, 2026Filing

    Insider Sell $3KCoen Steven P. · See remarks · $2.6K

  • Insider sellApr 14, 2026Filing

    Insider Sell $213KCoen Steven P. · See remarks · $212.8K

  • Insider sellApr 13, 2026Filing

    Insider Sell $802KShetty Reshma P. · Director, See remarks, 10% Owner · $802.5K

  • Insider sellApr 13, 2026Filing

    Insider Sell $802KCanton Barry · 10% Owner · $802.5K

  • Insider sellApr 10, 2026Filing

    Insider Sell $1.4MKelly Jason R · Director, See remarks · $1.4M

Questions

Frequently asked questions

What is Ginkgo Bioworks Holdings, Inc.'s market cap?

Ginkgo Bioworks Holdings, Inc. (DNA) has a market capitalization of $515.4M.

What is DNA's P/E ratio?

A meaningful P/E ratio is not available for DNA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is DNA's price-to-book (P/B) ratio?

DNA trades at 1.01 times book value per share.

Are insiders buying DNA stock?

SEC Form 4 filings show no open-market insider buys at Ginkgo Bioworks Holdings, Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.